Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Minority Interest: 2010-2025

Historic Minority Interest for Arrowhead Pharmaceuticals (ARWR) over the last 13 years, with Sep 2025 value amounting to $37.4 million.

  • Arrowhead Pharmaceuticals' Minority Interest rose 564.96% to $37.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 564.96%. This contributed to the annual value of $37.4 million for FY2025, which is 564.96% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Minority Interest stood at $37.4 million, which was up 1,590.39% from -$2.5 million recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Minority Interest peaked at $37.4 million during Q3 2025, and registered a low of -$2.5 million during Q2 2025.
  • For the 3-year period, Arrowhead Pharmaceuticals' Minority Interest averaged around $11.8 million, with its median value being $11.6 million (2024).
  • Examining YoY changes over the last 5 years, Arrowhead Pharmaceuticals' Minority Interest showed a top increase of 564.96% in 2025 and a maximum decrease of 129.75% in 2025.
  • Quarterly analysis of 4 years shows Arrowhead Pharmaceuticals' Minority Interest stood at $19.3 million in 2022, then plummeted by 31.17% to $13.3 million in 2023, then slumped by 73.80% to $3.5 million in 2024, then surged by 564.96% to $37.4 million in 2025.
  • Its last three reported values are $37.4 million in Q3 2025, -$2.5 million for Q2 2025, and $904,000 during Q1 2025.